13F Holdings
中文EN

PTCHF PureTech Health plc IFRS Annual reports only

Pharmaceutical Preparations · OTC · SEC CIK 1782999 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY45.0%
TTM net income YoY181.4%
TTM EPS YoY187.5%
Revenue 3-yr CAGR-34.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,818.9%
Net margin1,108.3%
FCF margin-2,783.3%
EBITDA margin-2,744.9%

Returns

ROE12.2%
ROA8.3%
ROIC (approx.)-66.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets32.3%
Debt / equity0.00x
Current ratio9.33x
Interest coverage-78.62x

Cash quality & payout

Operating cash flow / net income-2.51x
Accruals ratio29.0%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue$4.83M$3.33M$15.62M$17.39M$11.77M
R&D expense$69.45M$96.23M$152.43M$110.47M$81.86M
SG&A expense$71.47M$53.30M$60.99M$57.20M$49.44M
Operating income-$136.09M-$146.20M-$197.81M-$150.28M-$119.53M
Interest expense$1.73M$3.42M$3.94M$4.77M$2.95M
Pretax income$23.77M-$36.10M-$92.78M-$58.95M$18.97M
Income tax-$4.01M$30.52M-$55.72M$3.76M$14.40M
Net income$53.51M-$65.70M-$50.35M-$60.56M$5.99M
EBITDA-$132.52M-$141.27M-$188.91M-$143.00M-$112.89M
EPS (basic)0.21-0.24-0.18-0.210.02
EPS (diluted)0.21-0.24-0.18-0.210.02
Weighted avg. shares (diluted)256.03M276.30M284.76M286.59M—
Balance sheet
Cash & equivalents$280.64M$191.08M$149.87M$465.71M$403.88M
Receivables$1.52M$2.38M$11.87M$3.17M$2.56M
Current assets$386.26M$347.20M$386.19M$501.81M$414.35M
PP&E, netmay include right-of-use assets (IFRS)$7.07M$9.54M$22.96M$26.77M$22.78M
Intangibles—$906,000$831,000$987,000$899,000
Total assets$602.63M$693.97M$702.65M$946.01M$989.99M
Current liabilities$41.39M$51.37M$96.89M$226.13M$180.92M
Short-term debt—$0$5.16M$857,000$0
Long-term debt—$0$10.24M$14.26M$14.82M
Total debt—$0$15.40M$15.12M$14.82M
Total liabilities$194.70M$235.74M$155.06M$361.86M$336.45M
Shareholders' equity$414.71M$464.07M$542.22M$593.51M$669.75M
Net debt—-$191.08M-$134.47M-$450.59M-$389.06M
Shares outstanding—271.85M278.57M287.80M285.89M
Cash flow statement
Operating cash flow-$134.37M-$105.92M-$178.79M-$158.27M-$131.83M
Capital expenditure$11,000$70,000$2.18M$5.57M$5.17M
Free cash flow-$134.38M-$105.99M-$180.97M-$163.84M-$137.00M
Investing cash flow$240.89M$68.99M-$107.22M$197.38M$364.48M
Financing cash flow-$16.96M$78.14M-$29.83M$22.73M$38.87M
Depreciation & amortization$3.57M$4.93M$8.89M$7.29M$6.64M
Stock-based compensation$22.85M$4.42M$14.70M$13.95M$10.72M
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.